NASDAQ:PGEN - Get Free Report ) will be releasing its earnings data after the market closes on Tuesday, May 14th. Analysts expect Precigen to post earnings of ($0.09) per share for the quarter.
Get Precigen alerts:
Sign Up
Precigen (NASDAQ:PGEN - Get Free Report ) last announced its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). Precigen had a negative net margin of 1,540.63% and a negative return on equity of 55.47%. The company had revenue of $1.23 million during the quarter, compared to analysts' expectations of $2.03 million. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Precigen Stock Down 3.0 % PGEN traded down $0.04 on Thursday, reaching $1.29. The company had a trading volume of 745,363 shares, compared to its average volume of 1,007,941. Precigen has a 1 year low of $0.84 and a 1 year high of $1.88. The stock has a market capitalization of $321.11 million, a PE ratio of -3.31 and a beta of 1.77. The stock has a 50-day moving average price of $1.45 and a 200-day moving average price of $1.33.
Wall Street Analyst Weigh In A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. cut shares of Precigen from a "neutral" rating to an "underweight" rating in a report on Friday, March 22nd. JMP Securities reaffirmed a "market outperform" rating and issued a $14.00 target price on shares of Precigen in a report on Wednesday, March 20th. HC Wainwright reaffirmed a "buy" rating and issued a $6.00 target price on shares of Precigen in a report on Wednesday, March 20th. Finally, StockNews.com raised shares of Precigen to a "sell" rating in a report on Tuesday, March 26th.
Get Our Latest Report on PGEN
About Precigen (
Get Free Report )
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Read More
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
